We review design considerations for nucleic acid-based approaches and the challenges and next steps in developing therapeutic miRNA-targeting molecules for epilepsy.
The issue is federal Medicaid funding to states, which helps underwrite residential facilities for people with intellectual disabilities, and the conviction of some advocates and policymakers that larger settings like Misericordia should be discouraged.
This new technique poses a huge advantage because the results are more quantitative and rigid, which allows for clearer data and less subjectivity compared to the previous PET scan method.
During the three-day conference, key gaps and opportunities were identified and have been summarized in separate editorials from the Epilepsy Research Benchmark Stewards and patient advocacy organizations.
In conclusion, medium chain triglycerides are a promising adjunct to standard pharmacological treatment for both humans and dogs with epilepsy, as they lack central nervous system side effects found with current antiepileptic drugs.
Choice of an anti-seizure medication for first add-on requires consideration of many factors, many of which also apply to choose initial treatment.
Depression and anxiety are often comorbid in people with epilepsy.
The results of our study support the feasibility of using virtual care to deliver specialized outpatient care in a comprehensive epilepsy center.
